Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.39 |
| ▸ | DRD3 | P35462 | 8/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31326467 | 1.00 | DRD2 (0.39) | DRD2DRD3USP30HRH3ABCC9 | |
| SCHEMBL1768150 | 0.84 | CYP19A1 (0.43) | USP30HRH3CYP2D6CYP11B1CYP11B2 | |
| SCHEMBL1768475 | 0.81 | CYP11B1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL5569832 | 0.79 | DRD2 (0.48) | DRD2DRD3HRH3CYP2D6TSHR | |
| SCHEMBL1768139 | 0.78 | CYP11B1 (0.45) | CYP11B1CYP11B2 | |
| SCHEMBL1768144 | 0.76 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL2915675 | 0.76 | CYP1A2 (0.38) | CYP2D6TSHRNPSR1 | |
| SCHEMBL2914139 | 0.75 | DRD4 (0.33) | DRD3 | |
| SCHEMBL1768231 | 0.73 | AR (0.37) | — | |
| SCHEMBL2916901 | 0.69 | CYP17A1 (0.41) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887388-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887365-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-2004657-B1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| WO-2007116097-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | DRD2 4709/4885DRD3 3916/4885USP30 2479/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | DRD2 4709/4885DRD3 3916/4885USP30 2479/4885 |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | DRD2 4817/4885DRD3 4089/4885USP30 1793/4885 |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | DRD2 2563/4885DRD3 2190/4885USP30 2722/4885 |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | CYP11B1, CYP11B2, REN | DRD2 3420/4885DRD3 2822/4885USP30 3368/4885 |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP11B2, REN | DRD2 3458/4885DRD3 2840/4885USP30 3369/4885 |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | DRD2 3902/4885DRD3 3364/4885USP30 1351/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | DRD2 4817/4885DRD3 4089/4885USP30 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.